EC Offers Aid to Former AstraZeneca Workers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EC Offers Aid to Former AstraZeneca Workers



The European Commission is looking to provide Sweden with EUR4.3 million to help 700 workers affected by AstraZeneca job cuts to find new work. The proposal is currently awaiting approval from the European parliament and the EU’s Council of Ministers.

AstraZeneca announced plans earlier this year to axe approximately 7300 jobs worldwide. Almost 1000 of the job cuts will be in Sweden stemming from the closure of R&D sites in Lund and Umeå, and the limiting of operations in Mölndal and Södertälje. Of the 987 redundant workers, 700 who face the most difficulties in finding new jobs are being targeted for support. The estimated total cost of the support package is around EUR6.6 million, EUR4.3 million of which will come from the European Globalisation Adjustment Fund (EGF), which was established in 2006 with the aim of helping workers who have lost their jobs because of changing global trade patterns or the global financial crisis. Approximately EUR500 million is available each year to aid with job-search assistance, careers advice, tailor-made training and retraining, mentoring and promoting entrepreneurship.

In a statement, the EU Commissioner for Employment, Social Affairs and Inclusion, László Andor, said, "The pharmaceutical industry is currently undergoing significant changes in order to retain its competitiveness in a tough environment, and it is therefore increasingly seeking synergies to hold down the rising costs of R&D activities. I am confident that this proposal for EUR 4.3 million from Europe's Globalisation Fund would help to make the workers' transition to new jobs easier and faster."

Since the start of its operations in 2007, the EGF has received 101 applications, with more than EUR430 million being requested to help around 90481 workers. Applications are being received for a growing number of sectors and an increasing number of EU member states.

Related Articles

AstraZeneca Axe Hovers Above 7300 Workers

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here